KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Intangibles (2017 - 2024)

Aquestive Therapeutics has reported Intangibles over the past 8 years, most recently at $1.2 million for Q1 2024.

  • Quarterly results put Intangibles at $1.2 million for Q1 2024, down 11.25% from a year ago — trailing twelve months through Mar 2024 was $1.2 million (down 11.25% YoY), and the annual figure for FY2023 was $1.3 million, down 10.94%.
  • Intangibles for Q1 2024 was $1.2 million at Aquestive Therapeutics, down from $1.3 million in the prior quarter.
  • Over the last five years, Intangibles for AQST hit a ceiling of $7.4 million in Q2 2020 and a floor of $25000.0 in Q2 2022.
  • Median Intangibles over the past 5 years was $1.2 million (2024), compared with a mean of $1.5 million.
  • Biggest five-year swings in Intangibles: crashed 99.14% in 2021 and later soared 5328.0% in 2023.
  • Aquestive Therapeutics' Intangibles stood at $102000.0 in 2020, then crashed by 50.0% to $51000.0 in 2021, then soared by 2713.73% to $1.4 million in 2022, then dropped by 10.94% to $1.3 million in 2023, then dropped by 3.05% to $1.2 million in 2024.
  • The last three reported values for Intangibles were $1.2 million (Q1 2024), $1.3 million (Q4 2023), and $1.3 million (Q3 2023) per Business Quant data.